CU20140035A7 - Proteínas de función dual para tratar trastornos metabólicos - Google Patents
Proteínas de función dual para tratar trastornos metabólicosInfo
- Publication number
- CU20140035A7 CU20140035A7 CU2014000035A CU20140035A CU20140035A7 CU 20140035 A7 CU20140035 A7 CU 20140035A7 CU 2014000035 A CU2014000035 A CU 2014000035A CU 20140035 A CU20140035 A CU 20140035A CU 20140035 A7 CU20140035 A7 CU 20140035A7
- Authority
- CU
- Cuba
- Prior art keywords
- metabolic disorders
- dual function
- treat metabolic
- function proteins
- disorders associated
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 3
- 230000002503 metabolic effect Effects 0.000 abstract 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a la identificación de nuevas proteínas que comprenden el factor de crecimiento de fibroblastos 21 (FGF21) y otros reguladores metabólicos, incluyendo variantes de los mismos, conocidos por mejorar los perfiles metabólicos en sujetos en quienes se administren. También se divulgan métodos para tratar trastornos asociados con el FGF21, trastornos asociados con GLP-1, y trastornos asociados con Exendrina-4, incluyendo condiciones metabólicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161539290P | 2011-09-26 | 2011-09-26 | |
PCT/US2012/057371 WO2013049234A2 (en) | 2011-09-26 | 2012-09-26 | Dual function proteins for treating metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20140035A7 true CU20140035A7 (es) | 2014-08-28 |
Family
ID=47023090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2014000035A CU20140035A7 (es) | 2011-09-26 | 2014-03-26 | Proteínas de función dual para tratar trastornos metabólicos |
Country Status (26)
Country | Link |
---|---|
US (2) | US9458214B2 (es) |
EP (1) | EP2764019B1 (es) |
JP (1) | JP6152380B2 (es) |
KR (1) | KR102217254B1 (es) |
CN (2) | CN106432510A (es) |
AP (1) | AP2014007544A0 (es) |
AR (1) | AR088165A1 (es) |
AU (1) | AU2012316132A1 (es) |
BR (1) | BR112014007086A2 (es) |
CA (1) | CA2849760A1 (es) |
CL (1) | CL2014000737A1 (es) |
CO (1) | CO6920258A2 (es) |
CR (1) | CR20140141A (es) |
CU (1) | CU20140035A7 (es) |
EA (1) | EA201490697A1 (es) |
GT (1) | GT201400056A (es) |
IL (1) | IL231647A0 (es) |
MA (1) | MA35507B1 (es) |
MX (1) | MX350840B (es) |
PE (1) | PE20141542A1 (es) |
SG (1) | SG11201400596QA (es) |
TN (1) | TN2014000110A1 (es) |
TW (1) | TW201315742A (es) |
UY (1) | UY34347A (es) |
WO (1) | WO2013049234A2 (es) |
ZA (1) | ZA201401699B (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9006400B2 (en) | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
NZ701573A (en) | 2012-05-17 | 2017-04-28 | Extend Biosciences Inc | Carriers for improved drug delivery |
TW201420606A (zh) * | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
KR20150043505A (ko) * | 2012-09-07 | 2015-04-22 | 사노피 | 대사 증후군의 치료용 융합 단백질 |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods of regulating bile acid homeostasis and treatment of bile acid disorders and diseases |
EP4215205A1 (en) * | 2013-01-03 | 2023-07-26 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
JP6837840B2 (ja) | 2014-01-24 | 2021-03-10 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 結合タンパク質及びその使用方法 |
US20170065678A1 (en) * | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
EP3604498A1 (en) * | 2014-04-11 | 2020-02-05 | Université catholique de Louvain | Transgenic pig islets and uses thereof for treating diabetes |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
CA2994279A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
KR102670157B1 (ko) * | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
BR112018013820A2 (pt) | 2016-01-13 | 2018-12-11 | Novo Nordisk A/S | análogos de egf(a) com substituintes de ácido graxo |
JP7023518B2 (ja) * | 2016-05-25 | 2022-02-22 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 分泌障害の処置のための方法および組成物 |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
CN107759697B (zh) | 2016-08-19 | 2023-03-24 | 安源医药科技(上海)有限公司 | 制备融合蛋白的方法 |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
WO2018053201A1 (en) | 2016-09-14 | 2018-03-22 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
WO2018088838A1 (en) | 2016-11-10 | 2018-05-17 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
JP7244923B2 (ja) * | 2016-11-22 | 2023-03-23 | クロトー セラピューティクス インコーポレイテッド | 新規な組換えクロトータンパク質ならびにそれを含む組成物 |
WO2018115401A1 (en) * | 2016-12-22 | 2018-06-28 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
CN108570109B (zh) * | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | 包含免疫球蛋白Fc部分的双靶点融合蛋白 |
EP3612637A4 (en) * | 2017-04-21 | 2021-01-27 | Yuhan Corporation | DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
CA3068956A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Bifunctional compounds |
CN111629745A (zh) * | 2017-11-06 | 2020-09-04 | 夏尔-Nps医药品有限公司 | 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies) |
CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
CN109929806B (zh) * | 2017-12-19 | 2020-05-08 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
RS65720B1 (sr) * | 2017-12-22 | 2024-08-30 | Novartis Ag | Tretiranje metaboličkih poremećaja pomoću fgf21 varijanti |
CN113603794B (zh) * | 2018-01-11 | 2024-01-16 | 安源医药科技(上海)有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
WO2019154189A1 (en) | 2018-02-08 | 2019-08-15 | Sunshine Lake Pharma Co., Ltd. | Fgf21 variant, fusion protein and application thereof |
CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
EP3810183A1 (en) * | 2018-06-21 | 2021-04-28 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
EP3817720A2 (en) | 2018-07-03 | 2021-05-12 | Bristol-Myers Squibb Company | Fgf21 formulations |
WO2020028806A1 (en) | 2018-08-02 | 2020-02-06 | Duke University | Dual agonist fusion proteins |
KR20210082189A (ko) * | 2018-10-24 | 2021-07-02 | 샤이어-엔피에스 파마슈티칼즈, 인크. | Glp-2 융합 폴리펩티드 및 위장 병태를 치료 및 예방하기 위한 용도 |
CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
US20220251535A1 (en) * | 2019-02-20 | 2022-08-11 | Novo Nordisk A/S | Aminoacyl-trna synthetases and uses hereof |
CN111944055B (zh) * | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
CN115322794A (zh) * | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
US11981718B2 (en) * | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
WO2024102634A1 (en) * | 2022-11-07 | 2024-05-16 | Bp Asset Ix, Inc. | Fgf21 protein variant for the treatment of nash |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
EP1498425A1 (en) | 1986-05-05 | 2005-01-19 | The General Hospital Corporation | Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
ATE106249T1 (de) | 1987-11-05 | 1994-06-15 | Hybritech Inc | Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
ES2335386T3 (es) | 1999-11-18 | 2010-03-26 | Novartis Vaccines And Diagnostics, Inc. | Gen fgf-21 humano y productos de expresion genica. |
ATE339450T1 (de) | 1999-12-23 | 2006-10-15 | Zymogenetics Inc | Verfahren zur behandlung von entzündungen |
MXPA03009566A (es) | 2001-04-19 | 2004-12-06 | Scripps Research Inst | Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales. |
EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
KR20060135648A (ko) * | 2003-12-10 | 2006-12-29 | 일라이 릴리 앤드 캄파니 | 섬유모세포 성장인자 21의 뮤테인 |
EA011879B1 (ru) * | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
EP1846019A2 (en) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
PE20120021A1 (es) | 2008-10-10 | 2012-02-10 | Amgen Inc | Mutantes fgf21 |
KR101316159B1 (ko) | 2008-10-24 | 2013-10-15 | 아이알엠 엘엘씨 | 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형 |
WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
AU2010207721B2 (en) | 2009-01-23 | 2015-03-26 | Novo Nordisk A/S | FGF21 derivatives with albumin binder A-B-C-D-E- and their use |
CN101812474A (zh) * | 2009-02-25 | 2010-08-25 | 李慎涛 | 骨保护素-热休克蛋白65融合蛋白的制备及其应用 |
MX2011011815A (es) | 2009-05-05 | 2012-01-27 | Amgen Inc | Mutantes fgf21 y usos de los mismos. |
CN107188950B (zh) * | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | Fgf21突变体及其用途 |
JP2012529463A (ja) | 2009-06-11 | 2012-11-22 | ノヴォ ノルディスク アー/エス | 2型糖尿病を治療するための、glp−1とfgf21との組合せ |
CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
CN101993496B (zh) * | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
MX2012007318A (es) | 2009-12-22 | 2012-07-20 | Novartis Ag | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. |
EP2359843A1 (en) | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
US9006400B2 (en) | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
-
2012
- 2012-09-25 US US13/626,207 patent/US9458214B2/en active Active
- 2012-09-25 TW TW101135181A patent/TW201315742A/zh unknown
- 2012-09-25 UY UY0001034347A patent/UY34347A/es not_active Application Discontinuation
- 2012-09-26 AU AU2012316132A patent/AU2012316132A1/en not_active Abandoned
- 2012-09-26 PE PE2014000419A patent/PE20141542A1/es not_active Application Discontinuation
- 2012-09-26 EP EP12773169.3A patent/EP2764019B1/en active Active
- 2012-09-26 BR BR112014007086A patent/BR112014007086A2/pt not_active Application Discontinuation
- 2012-09-26 JP JP2014532112A patent/JP6152380B2/ja not_active Expired - Fee Related
- 2012-09-26 AP AP2014007544A patent/AP2014007544A0/xx unknown
- 2012-09-26 AR ARP120103552A patent/AR088165A1/es unknown
- 2012-09-26 MX MX2014003676A patent/MX350840B/es active IP Right Grant
- 2012-09-26 CA CA2849760A patent/CA2849760A1/en not_active Abandoned
- 2012-09-26 EA EA201490697A patent/EA201490697A1/ru unknown
- 2012-09-26 WO PCT/US2012/057371 patent/WO2013049234A2/en active Application Filing
- 2012-09-26 CN CN201610821947.8A patent/CN106432510A/zh active Pending
- 2012-09-26 SG SG11201400596QA patent/SG11201400596QA/en unknown
- 2012-09-26 KR KR1020147010943A patent/KR102217254B1/ko active IP Right Grant
- 2012-09-26 CN CN201280057819.0A patent/CN104024273B/zh active Active
-
2014
- 2014-03-07 ZA ZA2014/01699A patent/ZA201401699B/en unknown
- 2014-03-12 TN TNP2014000110A patent/TN2014000110A1/en unknown
- 2014-03-13 MA MA36823A patent/MA35507B1/fr unknown
- 2014-03-20 IL IL231647A patent/IL231647A0/en unknown
- 2014-03-25 CL CL2014000737A patent/CL2014000737A1/es unknown
- 2014-03-26 CR CR20140141A patent/CR20140141A/es unknown
- 2014-03-26 CU CU2014000035A patent/CU20140035A7/es unknown
- 2014-03-26 CO CO14064524A patent/CO6920258A2/es unknown
- 2014-03-26 GT GT201400056A patent/GT201400056A/es unknown
-
2016
- 2016-08-26 US US15/248,712 patent/US10669323B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20140035A7 (es) | Proteínas de función dual para tratar trastornos metabólicos | |
UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
CO7151525A2 (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
ECSP14013285A (es) | Variantes del factor 21 del crecimiento de fibroblastos | |
BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
UY32030A (es) | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
BR112015023020A2 (pt) | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas | |
BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
BR112014003704A2 (pt) | moduladores ror gama | |
WO2012125408A8 (en) | Pegylated apelin and uses thereof | |
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
GT201500168A (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
BR112015017432A2 (pt) | métodos para o tratamento de indicações cardiovasculares | |
BR112015007095A2 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados | |
TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders |